ImmunoSource
ActiveSummary
ImmunoSource has been active since 1993 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €1.4m and a net result of €92,739. Equity is growing by about 3.3% per year across the filed financial years. Its solvency ranks better than 95% of 5,566 sector peers (NACE 96, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
10-02
NBB filing
Annual accounts filed
financial year 2025 · micro format
2025
31-07
Financial
Liquidity more than doublescurrent ratio 53.11
Current ratio from 23.38 to 53.11; short-term debt falls from €61,699 to €26,194.
20-02
NBB filing
Annual accounts filed
financial year 2024 · micro format
2024
28-02
NBB filing
Annual accounts filed
financial year 2023 · micro format
2023
31-07
Financial
Liquidity more than doublescurrent ratio 24.20
Current ratio from 10.94 to 24.20; short-term debt falls from €135,099 to €59,159.
28-02
NBB filing
Annual accounts filed
financial year 2022 · micro format
2022
11-02
NBB filing
Annual accounts filed
financial year 2021 · micro format
2021
31-07
Financial
Highest result from 2019 to 2025net €192,642 ▲24.4%
Net result €192,642, the highest in the series.
26-02
NBB filing
Annual accounts filed
financial year 2020 · micro format
2020
28-02
NBB filing
Annual accounts filed
financial year 2019 · abbreviated format
2019
20-02
NBB filing
Annual accounts filed
financial year 2018 · abbreviated format
2018
31-01
NBB filing
Annual accounts filed
financial year 2017 · abbreviated format
2017
03-02
NBB filing
Annual accounts filed
financial year 2016 · abbreviated format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 31 annual accounts filed, the latest 10 are here; all are under Financials.
0 of 2 deeds read
About the unread acts
We know of 2 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.